Glow-in-the-Dark dye could help surgeons spot hidden cancer cells
NCT ID NCT06819228
First seen Oct 31, 2025 · Last updated Jun 23, 2026 · Updated 27 times
Summary
This early-phase trial is testing a fluorescent dye attached to the cancer drug panitumumab to help surgeons see head and neck cancer tissue during surgery. 18 adults with head and neck squamous cell carcinoma will receive the dye before their planned surgery. The goal is to find the best dose that makes cancer cells glow under a special camera, which may help surgeons remove all the cancer while sparing healthy tissue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HNSCC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Vanderbilt University Medical Center
RECRUITINGNashville, Tennessee, 37232, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Panitumumab-IRDye800 (a fluorescent dye attached to the drug panitumumab)
What this could lead to
If successful, this approach could help surgeons see cancer tissue more clearly during surgery, potentially leading to more complete tumor removal.
What could go wrong
This is a very early, small trial (18 people) focused on finding the right dose and testing imaging, not on treating the cancer. The dye may not improve outcomes or could have unexpected side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.